Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Valeant Pharmaceuticals Intl Inc (VRX) Buys Bausch & Lomb, Boosts The Cooper Companies, Inc. (COO) and Actavis Inc (ACT)

Page 1 of 2

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) stirred the merger and acquisition space once again with its announcement that it is about to acquire multinational eye health firm, Bausch & Lomb, for $8.7 billion in cash. Of the total amount, $4.5 billion will be paid to an investor group led by private equity firm Warburg Pincus, while the remaining amount will go toward repaying Bausch & Lomb’s outstanding debt. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has lined up a combination of debt and equity offerings to raise funds for the acquisition.

Valeant Pharmaceuticals Intl Inc (NYSE:VRX)

Bausch & Lomb has a great deal of history to their credit having invented the first soft contact lens. The company’s business portfolio is comprised of eye health products within three main business units, namely pharmaceutical, vision care, and surgical divisions. Following the acquisition, Bausch & Lomb is likely to become Valeant Pharmaceuticals Intl Inc (NYSE:VRX)’s ophthalmology division, boosting the latter’s existing portfolio of ophthalmology products. All cash deals carry a higher risk as opposed to share swap transactions and as such, it is an indicator that Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is looking forward to make it a success.

Why Valeant agreed to the deal

It is not difficult to see why Valeant Pharmaceuticals Intl Inc (NYSE:VRX) agreed to this aggressive deal. The transaction is likely to result in annual cost savings of at least $800 million by the end of 2014. In addition, the acquisition will start contributing to Valeant Pharmaceuticals Intl Inc (NYSE:VRX)’s bottom line from day one. Valeant expects the transaction will expand its eye care portfolio’s annual revenue of more than $3.5 billion. This will be quite a shift in focus for the company which has largely focused on dermatology so far. The expansion of the lucrative ophthalmology business is largely seen as positive by the market even though the acquisition is heavily funded by debt.

The Cooper Companies, Inc. (NYSE:COO) among indirect gainers

The deal also bodes well for The Cooper Companies, Inc. (NYSE:COO), which is a contact lens manufacturer and direct competitor of Bausch & Lomb. Wells Fargo analyst Larry Biegelsen projects that Valeant is likely to focus more on Bausch & Lomb’s pharmaceutical business than its contact lens business. This may seem baseless on the surface, but there is some element of truth in this logic as the stock gained nearly 4% after the announcement of the deal.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!